Reset filter
Mots-clés
Concomitant Medication ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

467 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Concomitant Medication Multiple Sclerosis ALAIN01 NCT02419378

- 28/05/2016 - 1 Formulaire, 2 Groupes Item, 14 Eléments de données, 1 Langue
Groupes Item: Concomitant Medication, Concomitant Medication
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany

NINDS CDE Drugs Epilepsy - Drugs

- 25/04/2016 - 1 Formulaire, 4 Groupes Item, 58 Eléments de données, 1 Langue
Groupes Item: Anti Epileptic Drug (AED) Plasma Concentration Log, Anti Epileptic Drug (AED) Resistance Log, Anti Epileptic Drug (AED) Log, Non Anti Epileptic Medication Log
NINDS Common Data Elements Used from the National Institute of Neurological Disorders and Stroke Common Data Elements (https://www.commondataelements.ninds.nih.gov/) References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods. Clin Trials. 2012;9(3):322-9.

NINDS CDE Prior and Concomitant Medications Amyotrophic Lateral Sclerosis - Prior and Concomitant Medications

- 15/04/2016 - 1 Formulaire, 1 Groupe Item, 14 Eléments de données, 1 Langue
Groupe Item: Prior and Concomitant Medications
NINDS Common Data Elements [Magnetic Resonance Imaging][Amyotrophic Lateral Sclerosis] Used from the National Institute of Neurological Disorders and Stroke Common Data Elements (https://www.commondataelements.ninds.nih.gov/) References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods. Clin Trials. 2012;9(3):322-9.

Concomitant medication Ponderosa CML ZKSJ0083 - Concomitant medication

- 20/03/2016 - 1 Formulaire, 1 Groupe Item, 8 Eléments de données, 1 Langue
Groupe Item: Concomitant medication
Study part: Concomitant medication.Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Concomitant medication LenaMain-Study - Concomitant Medication

- 17/03/2016 - 1 Formulaire, 1 Groupe Item, 11 Eléments de données, 1 Langue
Groupe Item: Concomitant medication
A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Protocol-Code: RV-MM-PI-280 EudraCT-Number: 2007-003945-33 Author: Claus Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr. med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann, Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-Studie: Prof. Roland Fenk, Düsseldorf Coordinating center for clinical trial Medical faculty of University Hospital Heinrich-Heine-University Scientific Director: Herr Dr. J. Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0) 211-81-19701 Fax: +49 (0) 211-81-19702

Concomitant medication Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv - Case Report Form (HIPEC) Concomitant medication

- 17/02/2016 - 1 Formulaire, 1 Groupe Item, 11 Eléments de données, 1 Langue
Groupe Item: Concomitant Medication Form
Phase 1 clinical trial for intrasurgical hyperthermic intraperitoneal chemoperfusion with cisplatin (HIPEC) in patients with ovarian cancer recidiv EudraCT Nr.: 2010-024352-28 Principal investigator und authorized representative of Sponsor: PD Dr. med. Oliver Zivanovic Center for Obstetrics and Gynaecology University Hospital Bonn Sigmund-Freud-Str. 25 53105 Bonn Sponsor: Rheinische Friedrich-Wilhelms-Universität Bonn represented by the Dean of Medical Faculty

Concomitant Medication AML Pazopanib NCT01361334

- 11/02/2016 - 1 Formulaire, 1 Groupe Item, 50 Eléments de données, 2 Langues
Groupe Item: Concomitant Medication
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible (PAZOPANIB-AML) https://clinicaltrials.gov/ct2/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany

Concomitant Medication AMLSG 21-13 DRKS00007189 NCT02013648 Akute myeloische Leukämie (AML) - Concomitant Medication AMLSG 21-13 NCT02013648 Akute myeloische Leukämie (AML)

- 11/02/2016 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Concomitant Medication, Signature
Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel(TM)) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Medication SIMPLIFy TAVI Transcatheter Aortic Valve Implantation Without Predilation NCT01539746 - Medication NCT01539746

- 04/02/2016 - 1 Formulaire, 1 Groupe Item, 10 Eléments de données, 1 Langue
Groupe Item: Medication
Use of the Self-Expanding CoreValve Prosthesis without Predilation in Patients with Significantly IMPaired Left-VentrIcular Ejection Fraction for Transcatheter Aortic Valve Implantation Study. Form is used in following visits: - Visit 4 (7 days +1d) - Visit 5 (30 days +15d) - Visit 6 (180 day +-30d) - Visit 7 (1 year +1m) Projektleiter (LKP): Prof. Dr. med. Georg Nickenig Medizinische Klinik und Poliklinik II Sigmund-Freud-Str. 25, 53125 Bonn Tel. 0228-287-15217, Fax 0228-287-16423 Email: georg.nickenig@ukb.uni-bonn.de

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487- End of Treatment - Supplemental page

- 06/08/2015 - 5 Formulaires, 22 Groupes Item, 81 Eléments de données, 1 Langue
Groupes Item: EXCEPTION, PREVIOUS AND CURRENT MEDICATIONS, PRE-TREATMENT EVENTS, BONE MARROW BIOPSY/ ASPIRATE, ELECTROCARDIOGRAM, CHEST X-RAY, TRANSFUSIONS, FLUORESCENT IN SITU HYBRIDIZATION, EXTERNAL DATA TRACKING, LABORATORY TEST RESULTS, DRUG DISPENSATION, BMS-354825 DOSING, CONCOMITANT MEDICATIONS, NON-SERIOUS ADVERSE EVENTS, DEATH DATA, ENROLLMENT IN PREVIOUS BMS CA180 PROTOCOL, DOSE ADMINISTRATION FOR UNSCHEDULED CSF, CSF PHARMACOKINETICS, BLOOD PHARMACOKINETICS, DOSE ADMINISTRATION, PLEURAL OR OTHER BODY FLUID PHARMACOKINETICS, DIAGNOSTIC PROCEDURES
Study documentation part: End of treatment. This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487- End of Treatment

10 Groupes Item 46 Eléments de données

Serious Adverse Event (SAE)- Form

3 Groupes Item 36 Eléments de données

Pharmacokinetics

4 Groupes Item 22 Eléments de données

Follow- Up

3 Groupes Item 11 Eléments de données

Melanoma Concomitant Medication NCT00110019 - Concomitant Medication Melanoma NCT00110019 E2603 No. 2169

- 26/03/2015 - 1 Formulaire, 2 Groupes Item, 29 Eléments de données, 2 Langues
Groupes Item: Header, Concomitant Medication
E2603 Concomitant Medication Form Form No. 2169 Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma NCT00110019 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=E7D649ED-D8C9-54BD-E034-0003BA3F9857

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial